ID   BCWM.1/BR
AC   CVCL_VJ29
SY   BCWM1-BR; BC/BR
DR   cancercelllines; CVCL_VJ29
DR   Wikidata; Q93424846
RX   PubMed=25382610;
CC   Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade).
CC   Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C80307; Waldenstrom macroglobulinemia
DI   ORDO; Orphanet_33226; Waldenstrom macroglobulinemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A035 ! BCWM.1
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 05-10-23; Version: 7
//
RX   PubMed=25382610; DOI=10.1038/bcj.2014.74;
RA   Chitta K.S., Paulus A., Caulfield T.R., Akhtar S., Blake M.K.K.,
RA   Ailawadhi S., Knight J., Heckman M.G., Pinkerton A.B., Chanan-Khan A.A.;
RT   "Nimbolide targets BCL2 and induces apoptosis in preclinical models of
RT   Waldenstroms macroglobulinemia.";
RL   Blood Cancer J. 4:e260.1-e260.10(2014).
//